NCT03624842|Unknown
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
1 other identifier
CTDH-AD-EA-001
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredAug 2018
Brief Summary
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 6, 2018
Completed4 days until next milestone
First Posted
Study publicly available on registry
August 10, 2018
CompletedLast Updated
August 10, 2018
Status Verified
August 1, 2018
First QC Date
August 6, 2018
Last Update Submit
August 6, 2018
Conditions
Interventions
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cyclo Therapeutics, Inc.lead
- Kerwin Research Center, LLCcollaborator
MeSH Terms
Conditions
Alzheimer Disease
Condition Hierarchy (Ancestors)
DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders
Study Officials
- PRINCIPAL INVESTIGATOR
Diana R Kerwin, MD
Kerwin Research Center
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 6, 2018
First Posted
August 10, 2018
Last Updated
August 10, 2018
Record last verified: 2018-08